Diabetic Foot Ulcers Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Diabetic Foot Ulcers Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The 7 major diabetic foot ulcers markets reached a value of US$ 3.5 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 5.4 Billion by 2034, exhibiting a growth rate (CAGR) of 3.96% during 2024-2034.

The diabetic foot ulcers market has been comprehensively analyzed in IMARC's new report titled "Diabetic Foot Ulcers Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Diabetic foot ulcers are a common complication of diabetes that occurs when there is damage to the nerves and blood vessels in the feet. This condition can reduce blood flow and decrease sensation in the feet, making them more vulnerable to injury, open sores, or wounds and slower to heal. The common indications of the ailment include swelling, large calluses or cracked heels, blisters, redness, sores, splinters, scrapes, pus, etc. The diagnosis of diabetic foot ulcers is typically made by a review of the patient's medical history, clinical features, and swab tests for secondary infection. Numerous laboratory investigations, including fasting blood sugar, a complete metabolic panel, glycated hemoglobin levels, erythrocyte sedimentation rate, a complete blood count, C-reactive protein, etc., are also utilized to confirm a diagnosis. The healthcare provider may perform X-rays among patients to evaluate the involvement of the bone.

The rising cases of chronic diabetes due to poor glycemic control coupled with the increasing unmet need for effective drugs to address this illness are primarily driving the diabetic foot ulcers market. Furthermore, the growing prevalence of several associated risk factors, such as foot deformities, ill-fitting footwear, underlying peripheral neuropathy, improper foot care, inadequate blood circulation, dry skin, etc., is also propelling the market growth. In addition to this, the escalating utilization of negative-pressure wound therapy, which uses sub-atmospheric pressure to minimize inflammatory exudate and encourage granulation tissue to optimize the physiology involved in wound healing, is creating a positive outlook for the market. Moreover, the inflating adoption of granulocyte-colony stimulating factors (G-CSF) for treating this ailment, since they improve clinical outcomes in patients by increasing the release of neutrophils from the bone marrow and enhancing their function, is also bolstering the market growth. Apart from this, the emerging popularity of tissue-engineered skin substitutes that are designed using living cells, like fibroblasts, keratinocytes, stem cells, etc., to replace or supplement damaged skin and promote wound healing is expected to drive the diabetic foot ulcers market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the diabetic foot ulcers market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for diabetic foot ulcers and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the diabetic foot ulcers market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the diabetic foot ulcers market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the diabetic foot ulcers market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current diabetic foot ulcers marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the diabetic foot ulcers market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the diabetic foot ulcers market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the diabetic foot ulcers market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (​2018-2034​) of diabetic foot ulcers across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of diabetic foot ulcers by age across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of diabetic foot ulcers by gender across the seven major markets?
How many patients are diagnosed (​2018-2034​) with diabetic foot ulcers across the seven major markets?
What is the size of the diabetic foot ulcers patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of diabetic foot ulcers?
What will be the growth rate of patients across the seven major markets?

Diabetic Foot Ulcers: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for diabetic foot ulcers drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the diabetic foot ulcers market?
What are the key regulatory events related to the diabetic foot ulcers market?
What is the structure of clinical trial landscape by status related to the diabetic foot ulcers market?
What is the structure of clinical trial landscape by phase related to the diabetic foot ulcers market?
What is the structure of clinical trial landscape by route of administration related to the diabetic foot ulcers market?